Synopsis
Synopsis
0
VMF
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. 3 Alpha,7 Beta Dihydroxy 5 Beta Cholan 24 Oic Acid
2. 3 Alpha,7 Beta-dihydroxy-5 Beta-cholan-24-oic Acid
3. Acid, Deoxyursocholic
4. Acid, Ursacholic
5. Acid, Ursodeoxycholic
6. Cholit-ursan
7. Cholofalk
8. Delursan
9. Deoxyursocholic Acid
10. Destolit
11. Sodium Ursodeoxycholate
12. Urdox
13. Ursacholic Acid
14. Urso
15. Urso Heumann
16. Ursobilane
17. Ursochol
18. Ursodeoxycholate, Sodium
19. Ursodiol
20. Ursofalk
21. Ursogal
22. Ursolite
23. Ursolvan
1. Ursodiol
2. 128-13-2
3. Actigall
4. Ursodeoxycholate
5. Udca
6. Ursofalk
7. Ursolvan
8. Urso
9. Delursan
10. Ursodesoxycholic Acid
11. Urso Forte
12. Destolit
13. Ursochol
14. Cholit-ursan
15. Litursol
16. Solutrat
17. Ursobilin
18. Ursodamor
19. Arsacol
20. Deursil
21. Lyeton
22. Ursacol
23. Urso Ds
24. Udcs
25. 3alpha,7beta-dihydroxy-5beta-cholan-24-oic Acid
26. Ursosan
27. Urso 250
28. 3-alpha,7-beta-dioxycholanic Acid
29. Ursocholic Acid, Deoxy-
30. 3-alpha,7-beta-dihydroxycholanic Acid
31. Ursonorm
32. Nsc 683769
33. (3alpha,5beta,7beta)-3,7-dihydroxycholan-24-oic Acid
34. 3-alpha,7-beta-dihydroxy-5-beta-cholanoic Acid
35. Ursodeoxycholicacid
36. (4r)-4-[(3r,5s,7s,8r,9s,10s,13r,14s,17r)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoic Acid
37. Nsc 657950
38. Brn 3219888
39. 3,7-dihydroxycholan-24-oic Acid
40. Peptarom
41. Ursodeoxycholic Acid [inn]
42. Chembl1551
43. Mls000028461
44. Chebi:9907
45. 724l30y2qr
46. Nsc-683769
47. Ursodiol [usan]
48. Antigall
49. Smr000058403
50. Urosiol
51. Cholan-24-oic Acid, 3,7-dihydroxy-, (3.alpha.,5.beta.,7.beta.)-
52. 7-beta-hydroxylithocholic Acid
53. Ursodexycholic Acid
54. Acido Ursodeossicolico [italian]
55. (r)-4-((3r,5s,7s,8r,9s,10s,13r,14s,17r)-3,7-dihydroxy-10,13-dimethylhexadecahydro-1h-cyclopenta[a]phenanthren-17-yl)pentanoic Acid
56. Acido Ursodeoxicolico
57. Acido Ursodeossicolico
58. Acido Ursodeoxicolico [inn-spanish]
59. Acidum Ursodeoxycholicum [inn-latin]
60. Acide Ursodesoxycholique
61. Acide Ursodesoxycholique [inn-french]
62. Acidum Ursodeoxycholicum
63. Actigall (tn)
64. Ursodiol (usp)
65. (4r)-4-[(1s,2s,5r,7s,9s,10r,11s,14r,15r)-5,9-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl]pentanoic Acid
66. Ccris 5502
67. Urso (tn)
68. Sr-01000737091
69. Ursodiol [usan:usp]
70. Einecs 204-879-3
71. Mfcd00003680
72. Ursodexycholate
73. Paptarom
74. Udiliv
75. Desol
76. Urdes
77. Unii-724l30y2qr
78. Urosdesoxycholate
79. 17-beta-(1-methyl-3-carboxypropyl)etiocholane-3-alpha,7-beta-diol
80. Ursodeoxycholoc Acid
81. Urosdesoxycholic Acid
82. 5beta-cholanic Acid-3alpha,7beta-diol
83. Ursodiol [inci]
84. Cholan-24-oic Acid, 3,7-dihydroxy-, (3alpha,5beta,7beta)-
85. 3alpha,7beta-dihydroxy-5beta-cholanic Acid
86. Ursodiol [mi]
87. Ursodiol (actigal Urso)
88. Ursodiol [vandf]
89. Prestwick0_000958
90. Prestwick1_000958
91. Prestwick2_000958
92. Prestwick3_000958
93. U0030
94. 7a-hydroxylithocholic Acid
95. Ursodiol [usp-rs]
96. Ec 204-879-3
97. U-9000
98. Schembl27200
99. Bspbio_000956
100. 4-10-00-01604 (beilstein Handbook Reference)
101. 7bet.-hydroxylithocholic Acid
102. Cid_31401
103. Mls001066373
104. Mls002548885
105. Spbio_003105
106. Ursodeoxycholic Acid, >=99%
107. Ursodiol [orange Book]
108. Bpbio1_001052
109. Gtpl7104
110. 7.beta.-hydroxylithocholic Acid
111. Ursodiol (ursodeoxycholic Acid)
112. 5-beta-cholan-24-oic Acid, 3-alpha,7-beta-dihydroxy-
113. Dtxsid6023731
114. Ursodiol [usp Monograph]
115. Bdbm53721
116. (3alpha,5beta,7beta,8xi)-3,7-dihydroxycholan-24-oic Acid
117. Hms1570p18
118. Hms2097p18
119. Hms2233l14
120. Hms3259a13
121. Hms3714p18
122. Ursodeoxycholic Acid (jp17/inn)
123. Ursodeoxycholic Acid [jan]
124. 3alpha,7beta-dihydroxycholanic Acid
125. Act02676
126. Cholan-24-oic Acid, 3,7-dihydroxy-, (3-alpha,5-beta,7-beta)-
127. Zinc3914809
128. 3a,7b-dihydroxy-5b-cholan-24-oate
129. Lmst04010033
130. S1643
131. Ursodeoxycholic Acid [mart.]
132. Ursodeoxycholic Acid [who-dd]
133. 5a-cholan-24-oic Acid-3a,7a-diol
134. Akos015955898
135. Ccg-220958
136. Cs-1932
137. Db01586
138. Ks-5243
139. Nc00487
140. Smp2_000012
141. 3.alpha.,7.beta.-dihydroxycholanic Acid
142. 3a,7a-dihydroxy-5a-holan-24-oic Acid
143. 3a,7b-dihydroxy-5b-cholan-24-oic Acid
144. Ncgc00179363-01
145. Ncgc00179363-12
146. Ac-18919
147. Cas#128-13-2
148. Cpd000058403
149. Hy-13771
150. Nci60_028904
151. Ursodeoxycholic Acid [ep Impurity]
152. Ursodeoxycholic Acid [ep Monograph]
153. Ab00513977
154. (3a,5b,7b)-3,7-dihydroxy-cholan-24-oate
155. 3alpha, 7beta-dihydroxy-5beta-cholanoic Acid
156. 5bet.-cholan-24-oic Acid-3alp.,7bet.-diol
157. (3a,5b,7b)-3,7-dihydroxycholan-24-oic Acid
158. C07880
159. D00734
160. ((3a,5b,7b)-3,7-dihydroxycholan-24-oic Acid
161. (3a,5b,7b)-3,7-dihydroxy-cholan-24-oic Acid
162. Ab00513977-09
163. Ab00513977_10
164. 3alp.,7bet.-dihydroxy-5bet.-cholan-24-oic Acid
165. A905413
166. Q241374
167. 3.alpha.,7.beta.-dihydroxy-5.beta.-cholanic Acid
168. J-005566
169. J-650210
170. Sr-01000737091-3
171. Sr-01000737091-4
172. Brd-k15697815-001-16-2
173. 3.alpha.,7.beta.-dihydroxy-5.beta.-cholan-24-oic Acid
174. Z2786051717
175. 3.alpha.,7.beta.-dihydroxy-5b-cholan-24-oic Acid
176. 5.beta.-cholan-24-oic Acid, 3.alpha.,7.beta.-dihydroxy-
177. Ursodiol, United States Pharmacopeia (usp) Reference Standard
178. Ursodeoxycholic Acid, British Pharmacopoeia (bp) Reference Standard
179. Ursodeoxycholic Acid, European Pharmacopoeia (ep) Reference Standard
180. 17.beta.-(1-methyl-3-carboxypropyl)etiocholane-3.alpha.,7.beta.-diol
181. 3,7-dihydroxycholan-24-oic Acid-, (3.alpha.,5.beta.,7.beta.)- #
182. Ursodeoxycholic Acid, 500 Mug/ml In Methanol, Certified Reference Material
183. Ursodiol, Pharmaceutical Secondary Standard; Certified Reference Material
184. Ursodeoxycholic Acid For System Suitability, European Pharmacopoeia (ep) Reference Standard
185. (4r)-4-[(1s,2s,5r,7s,9s,10r,11s,14r,15r)-5,9-dihydroxy-2,15-dimethyltetracyclo[8.7.0.02,1.011,1]heptadecan-14-yl]pentanoic Acid
186. (4r)-4-[(3r,5s,7s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-3,7-bis(oxidanyl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoic Acid
187. (4r)-4-[(3r,5s,7s,8r,9s,10s,13r,14s,17r)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]valeric Acid
188. 108609-27-4
| Molecular Weight | 392.6 g/mol |
|---|---|
| Molecular Formula | C24H40O4 |
| XLogP3 | 4.9 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 4 |
| Exact Mass | 392.29265975 g/mol |
| Monoisotopic Mass | 392.29265975 g/mol |
| Topological Polar Surface Area | 77.8 Ų |
| Heavy Atom Count | 28 |
| Formal Charge | 0 |
| Complexity | 605 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 10 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 8 | |
|---|---|
| Drug Name | Actigall |
| Drug Label | Actigall is a bile acid available as 300 mg capsules suitable for oral administration.Actigall is ursodiol, USP (ursodeoxycholic acid), a naturally occurring bile acid found in small quantities in normal human bile and in the biles of certain other m... |
| Active Ingredient | Ursodiol |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | 300mg |
| Market Status | Prescription |
| Company | Watson Pharms |
| 2 of 8 | |
|---|---|
| Drug Name | Urso 250 |
| PubMed Health | Ursodiol (By mouth) |
| Drug Classes | Gastrointestinal Agent |
| Drug Label | URSO 250 (ursodiol, 250 mg) is available as a film-coated tablet for oral administration. URSO Forte (ursodiol, 500 mg) is available as a scored film-coated tablet for oral administration. Ursodiol (ursodeoxycholic acid, UDCA) is a naturally occurrin... |
| Active Ingredient | Ursodiol |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 250mg |
| Market Status | Prescription |
| Company | Forest Labs |
| 3 of 8 | |
|---|---|
| Drug Name | Urso forte |
| PubMed Health | Ursodiol (By mouth) |
| Drug Classes | Gastrointestinal Agent |
| Drug Label | URSO 250 (ursodiol, 250 mg) is available as a film-coated tablet for oral administration. URSO Forte (ursodiol, 500 mg) is available as a scored film-coated tablet for oral administration. Ursodiol (ursodeoxycholic acid, UDCA) is a naturally occurrin... |
| Active Ingredient | Ursodiol |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 500mg |
| Market Status | Prescription |
| Company | Forest Labs |
| 4 of 8 | |
|---|---|
| Drug Name | Ursodiol |
| PubMed Health | Ursodiol (By mouth) |
| Drug Classes | Gastrointestinal Agent |
| Drug Label | Ursodiol Capsules, USP are a bile acid available as 300 mg capsules suitable for oral administration.Ursodiol, USP (ursodeoxycholic acid) is a naturally occurring bile acid found in small quantities in normal human bile and in the biles of certain ot... |
| Active Ingredient | Ursodiol |
| Dosage Form | Tablet; Capsule |
| Route | Oral |
| Strength | 250mg; 500mg; 300mg |
| Market Status | Prescription |
| Company | Corepharma; Epic Pharma; Par Pharm; Glenmark Generics; Teva Pharms; Lannett; Mylan; Impax Labs |
| 5 of 8 | |
|---|---|
| Drug Name | Actigall |
| Drug Label | Actigall is a bile acid available as 300 mg capsules suitable for oral administration.Actigall is ursodiol, USP (ursodeoxycholic acid), a naturally occurring bile acid found in small quantities in normal human bile and in the biles of certain other m... |
| Active Ingredient | Ursodiol |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | 300mg |
| Market Status | Prescription |
| Company | Watson Pharms |
| 6 of 8 | |
|---|---|
| Drug Name | Urso 250 |
| PubMed Health | Ursodiol (By mouth) |
| Drug Classes | Gastrointestinal Agent |
| Drug Label | URSO 250 (ursodiol, 250 mg) is available as a film-coated tablet for oral administration. URSO Forte (ursodiol, 500 mg) is available as a scored film-coated tablet for oral administration. Ursodiol (ursodeoxycholic acid, UDCA) is a naturally occurrin... |
| Active Ingredient | Ursodiol |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 250mg |
| Market Status | Prescription |
| Company | Forest Labs |
| 7 of 8 | |
|---|---|
| Drug Name | Urso forte |
| PubMed Health | Ursodiol (By mouth) |
| Drug Classes | Gastrointestinal Agent |
| Drug Label | URSO 250 (ursodiol, 250 mg) is available as a film-coated tablet for oral administration. URSO Forte (ursodiol, 500 mg) is available as a scored film-coated tablet for oral administration. Ursodiol (ursodeoxycholic acid, UDCA) is a naturally occurrin... |
| Active Ingredient | Ursodiol |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 500mg |
| Market Status | Prescription |
| Company | Forest Labs |
| 8 of 8 | |
|---|---|
| Drug Name | Ursodiol |
| PubMed Health | Ursodiol (By mouth) |
| Drug Classes | Gastrointestinal Agent |
| Drug Label | Ursodiol Capsules, USP are a bile acid available as 300 mg capsules suitable for oral administration.Ursodiol, USP (ursodeoxycholic acid) is a naturally occurring bile acid found in small quantities in normal human bile and in the biles of certain ot... |
| Active Ingredient | Ursodiol |
| Dosage Form | Tablet; Capsule |
| Route | Oral |
| Strength | 250mg; 500mg; 300mg |
| Market Status | Prescription |
| Company | Corepharma; Epic Pharma; Par Pharm; Glenmark Generics; Teva Pharms; Lannett; Mylan; Impax Labs |
The drug decreases the absorption of cholesterol and is used to dissolve (cholesterol) gallstones in patients as an alternative to a surgical procedure to remove the gallstones.
FDA Label
Ursodiol (commonly known as ursodeoxycholic acid) is a product of metabolism of bacteria in the intestine. It is considered a secondary bile acid. The other type of bile acid, primary bile acids, are produced hepatically and subsequently stored in the gallbladder. When primary bile acids are secreted into the large intestine, they can be broken down into secondary bile acids by bacteria present in the intestine. Both types of bile acids assist in the metabolism of dietary fat. Ursodeoxycholic acid regulates cholesterol levels by slowing the rate at which the intestine is able to absorb cholesterol and also acts to break down micelles, which contain cholesterol. Because of this property, ursodeoxycholic acid is used to treat gall stones non-surgically.
Cholagogues and Choleretics
Gastrointestinal agents that stimulate the flow of bile into the duodenum (cholagogues) or stimulate the production of bile by the liver (choleretic). (See all compounds classified as Cholagogues and Choleretics.)
A05AA02
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
A - Alimentary tract and metabolism
A05 - Bile and liver therapy
A05A - Bile therapy
A05AA - Bile acids and derivatives
A05AA02 - Ursodeoxycholic acid
Route of Elimination
Only small quantities of ursodiol appear in the systemic circulation and very small amounts are excreted into urine. Eighty percent of lithocholic acid formed in the small bowel is excreted in the feces, but the 20% that is absorbed is sulfated at the 3-hydroxyl group in the liver to relatively insoluble lithocholyl conjugates which are excreted into bile and lost in feces.
Ursodeoxycholic acid reduces elevated liver enzyme levels by facilitating bile flow through the liver and protecting liver cells. The main mechanism if anticholelithic. Although the exact process of ursodiol's anticholelithic action is not completely understood, it is thought that the drug is concentrated in bile and decreases biliary cholesterol by suppressing hepatic synthesis and secretion of cholesterol and by inhibiting its intestinal absorption. The reduced cholesterol saturation permits the gradual solubilization of cholesterol from gallstones, resulting in their eventual dissolution.
Certificate Number : R1-CEP 2012-277 - Rev 00
Issue Date : 2018-08-10
Type : Chemical and TSE
Substance Number : 1275
Status : Valid
Registration Number : 303MF10073
Registrant's Address : Via Pavia, 1-27027 Gropello Cairoli, Pavia, Italy
Initial Date of Registration : 2021-04-27
Latest Date of Registration :
Registrant Name : Eltek Pharmachem Co., Ltd.
Registration Date : 2020-08-13
Registration Number : 20200813-211-J-501
Manufacturer Name : Farmabios SPA
Manufacturer Address : Via Pavia 1-27027, GROPELLO CAIROLI (PV), Italy
| Available Reg Filing : EU, BR |
ICE Pharma offers a unique range of bile acid products and best-in-class services for the pharmaceutical industry.
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-03-25
Pay. Date : 2019-02-14
DMF Number : 16803
Submission : 2003-09-03
Status : Active
Type : II
Certificate Number : R1-CEP 2014-231 - Rev 00
Issue Date : 2020-04-21
Type : Chemical
Substance Number : 1275
Status : Valid
Registration Number : 218MF10319
Registrant's Address : Via Sicilia, 8/10 42122 Reggio Emilia, ITALY
Initial Date of Registration : 2006-03-09
Latest Date of Registration :
Date of Issue : 2021-11-01
Valid Till : 2024-10-31
Written Confirmation Number : WC-0512
Address of the Firm :
NDC Package Code : 49345-2612
Start Marketing Date : 2002-05-20
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Kukjeon Pharmaceutical Co., Ltd.
Registration Date : 2020-07-16
Registration Number : 20200716-211-J-434
Manufacturer Name : ICE SPA@Raichem Medicare Pvt. Ltd
Manufacturer Address : Via Sicilia, 8-10-42122 Reggio Nell' Emilia (RE) Italy@Plot Nos. 24, 25, 26 & 26P, Raichur Industrial Growth Centre, Chicksugur Village, Raichur Dist –584 134, India
Octavius Pharma has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.
Delivering Quality APIs, Drug Intermediates, and Specialty Chemicals to Over 50 Countries Across the Globe.
Delivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.
Certificate Number : R1-CEP 2009-212 - Rev 00
Issue Date : 2015-10-26
Type : Chemical and TSE
Substance Number : 1275
Status : Valid
| Available Reg Filing : EU, BR |
Certificate Number : CEP 2018-115 - Rev 01
Issue Date : 2024-06-17
Type : Chemical and TSE
Substance Number : 1275
Status : Valid
| Available Reg Filing : EU, BR |
ICE Pharma offers a unique range of bile acid products and best-in-class services for the pharmaceutical industry.
Certificate Number : CEP 2005-198 - Rev 07
Issue Date : 2024-07-24
Type : Chemical and TSE
Substance Number : 1275
Status : Valid
ICE Pharma offers a unique range of bile acid products and best-in-class services for the pharmaceutical industry.
Certificate Number : CEP 2010-376 - Rev 03
Issue Date : 2025-07-22
Type : Chemical and TSE
Substance Number : 1275
Status : Valid
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
ICE Pharma offers a unique range of bile acid products and best-in-class services for the pharmaceutical industry.
NDC Package Code : 49345-2612
Start Marketing Date : 2002-05-20
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 22365-012
Start Marketing Date : 2018-12-17
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 46438-0090
Start Marketing Date : 2005-11-17
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 46438-0654
Start Marketing Date : 2005-11-17
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 62991-2185
Start Marketing Date : 2009-11-03
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT

NDC Package Code : 38779-1987
Start Marketing Date : 2014-06-16
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN P...

NDC Package Code : 51927-2909
Start Marketing Date : 1999-07-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...

NDC Package Code : 61200-001
Start Marketing Date : 2013-11-26
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER, FOR SUSPENSION (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...

NDC Package Code : 49452-8085
Start Marketing Date : 2000-09-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT

NDC Package Code : 70294-103
Start Marketing Date : 2024-02-07
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]About the Company : Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-qual...
ICE Pharma offers a unique range of bile acid products and best-in-class services for the pharmaceutical industry.
About the Company : ICE Pharma's core business includes the manufacture of active pharmaceutical ingredients, the most important of which is Ursodeoxycholic Acid (UDCA), used to treat liver diseases a...
About the Company : Symbiotec, a leading API manufacturing company based in Indore, Central India, specializes in Cortico-Steroids and Steroid-Hormone APIs. Since 1995, their focus on R&D, sustainable...
Octavius Pharma has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.
About the Company : Octavius Pharma is a global leader in Directly Compressible Granules with over 45 years of expertise in formulation development, manufacturing, and commercialization. Our portfolio...
Delivering Quality APIs, Drug Intermediates, and Specialty Chemicals to Over 50 Countries Across the Globe.
About the Company : Zeal MediPharma is a globally recognized Star One Export House, serving customers in over 50 countries for more than two decades. We specialize in sourcing and exporting high-quali...
Delivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.
About the Company : Mankind Pharma, came into existence in 1986. In 1991, the company was formed into a legal corporation. However, it actively started working as a fully integrated pharmaceutical com...
About the Company : HENGDIAN GROUP was established in 1975, till now it has become a transnational,conglomerate group and been one of the largest private-owned enterprises in China. The Pharmaceutical...

About the Company : Otto Brandes Gmbh was founded in 1923 and is an independent distributor of high quality Pharmaceutical Active Ingredients and excipients for the pharmaceutical industry. We regard ...

About the Company : Founded in 1980, Sichuan Xieli Pharmaceutical Co., Ltd. operates with the guiding principle of "collaborating to build a healthy enterprise." The company specializes in the cultiva...

About the Company : Suzhou Tianlu Bio-pharmaceutical Co.,Ltd., established in Dec.1999 covering an area of 26,666 square meters, is a high-tech shareholding company with a total investment of one hund...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Strides Pharma, has received approval for Ursodiol Capsules USP, 300 mg from the USFDA. The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Actigall® Capsules, 300 mg, of Allergan Sales, LLC.
Lead Product(s): Ursodeoxycholic Acid,Inapplicable
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Urso Forte-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 25, 2021
Lead Product(s) : Ursodeoxycholic Acid,Inapplicable
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Strides Receives USFDA Approval for Ursodiol Capsules
Details : Strides Pharma, has received approval for Ursodiol Capsules USP, 300 mg from the USFDA. The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Actigall® Capsules, 300 mg, of Allergan Sales, LLC.
Product Name : Urso Forte-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 25, 2021
Details:
USFDA approved generic version of Ursodiol Tablet, which is indicated for the treatment of patients with Primary Biliary Cirrhosis. It inhibits the absorption of cholesterol in the intestine and the secretion of cholesterol into bile, decreasing biliary cholesterol saturation.
Lead Product(s): Ursodeoxycholic Acid,Inapplicable
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Urso Forte-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 21, 2020
Lead Product(s) : Ursodeoxycholic Acid,Inapplicable
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Strides Receives USFDA Approval for Ursodiol Tablets
Details : USFDA approved generic version of Ursodiol Tablet, which is indicated for the treatment of patients with Primary Biliary Cirrhosis. It inhibits the absorption of cholesterol in the intestine and the secretion of cholesterol into bile, decreasing biliary ...
Product Name : Urso Forte-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 21, 2020
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Norursodeoxycholic acid is a synthetic derivative of UDCA, shows promise for Non-Alcoholic Fatty Liver Disease by activating the AMPK pathway to reduce liver fat, inflammation, and apoptosis.
Lead Product(s): Ursodeoxycholic Acid,Inapplicable
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 14, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ursodeoxycholic Acid,Inapplicable
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Shilpa Medicare's NorUDCA Makes History as First Approved NAFLD Therapy Worldwide
Details : Norursodeoxycholic acid is a synthetic derivative of UDCA, shows promise for Non-Alcoholic Fatty Liver Disease by activating the AMPK pathway to reduce liver fat, inflammation, and apoptosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 14, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Chenodeoxycholic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Cholelithiasis.
Lead Product(s): Chenodeoxycholic Acid,Ursodeoxycholic Acid
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 05, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Chenodeoxycholic Acid,Ursodeoxycholic Acid
Therapeutic Area : Gastroenterology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of CnU Capsule 750 mg Safety & Efficacy in Patients with Cholesterol Gallstones
Details : Chenodeoxycholic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Cholelithiasis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 05, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Under the licensing agreement, Ipsen’s Iqirvo (elafibranor) has been granted pricing and reimbursement in Italy for Primary Biliary Cholangitis.
Lead Product(s): Elafibranor,Ursodeoxycholic Acid
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Iqirvo
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Ipsen
Deal Size: $542.8 million Upfront Cash: $135.7 million
Deal Type: Licensing Agreement May 20, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Elafibranor,Ursodeoxycholic Acid
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Ipsen
Deal Size : $542.8 million
Deal Type : Licensing Agreement
GENFIT to Receive €26.5M Milestone After Ipsen’s Iqirvo® Pricing Approval in Italy
Details : Under the licensing agreement, Ipsen’s Iqirvo (elafibranor) has been granted pricing and reimbursement in Italy for Primary Biliary Cholangitis.
Product Name : Iqirvo
Product Type : Miscellaneous
Upfront Cash : $135.7 million
May 20, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Norursodeoxycholic acid is an engineered bile acid derivative, which is currently being evaluated for the treatment of primary sclerosing cholangitis.
Lead Product(s): Ursodeoxycholic Acid,Inapplicable
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 07, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ursodeoxycholic Acid,Inapplicable
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Dr. Falk Shows Phase 3 Success for Norucholic Acid in PSC Treatment
Details : Norursodeoxycholic acid is an engineered bile acid derivative, which is currently being evaluated for the treatment of primary sclerosing cholangitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 07, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Livdelzi (seladelpar) is a novel selective, first-in-class, PPAR delta agonist, indicated to treat adults with primary biliary cholangitis (PBC).
Lead Product(s): Seladelpar Lysine,Ursodeoxycholic Acid
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Livdelzi
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 20, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Seladelpar Lysine,Ursodeoxycholic Acid
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Gilead’s Seladelpar Gets Conditional Approval for Primary Biliary Cholangitis
Details : Livdelzi (seladelpar) is a novel selective, first-in-class, PPAR delta agonist, indicated to treat adults with primary biliary cholangitis (PBC).
Product Name : Livdelzi
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 20, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Livdelzi (seladelpar) is a novel selective, first-in-class, PPAR delta agonist, indicated to treat adults with primary biliary cholangitis (PBC).
Lead Product(s): Seladelpar Lysine,Ursodeoxycholic Acid
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Livdelzi
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 13, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Seladelpar Lysine,Ursodeoxycholic Acid
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Gilead’s Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis
Details : Livdelzi (seladelpar) is a novel selective, first-in-class, PPAR delta agonist, indicated to treat adults with primary biliary cholangitis (PBC).
Product Name : Livdelzi
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 13, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Obeticholic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Liver Cirrhosis, Biliary.
Lead Product(s): Obeticholic Acid,Ursodeoxycholic Acid
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 04, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Obeticholic Acid,Ursodeoxycholic Acid
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Obeticholic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Liver Cirrhosis, Biliary.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 04, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Ursodiol is indicated for the treatment of patients with Primary Biliary Cirrhosis. It inhibits the absorption of cholesterol and the secretion of cholesterol.
Lead Product(s): Ursodeoxycholic Acid,Inapplicable
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Urso DS-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 22, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ursodeoxycholic Acid,Inapplicable
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Sunshine Biopharma Launches a New Generic Prescription Drug
Details : Ursodiol is indicated for the treatment of patients with Primary Biliary Cirrhosis. It inhibits the absorption of cholesterol and the secretion of cholesterol.
Product Name : Urso DS-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 22, 2024

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]RLD : No
TE Code : AB
Brand Name : URSODIOL
Dosage Form : CAPSULE;ORAL
Dosage Strength : 300MG
Approval Date : 2021-01-22
Application Number : 210344
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : URSODIOL
Dosage Form : TABLET;ORAL
Dosage Strength : 250MG
Approval Date : 2020-08-20
Application Number : 213504
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : URSODIOL
Dosage Form : TABLET;ORAL
Dosage Strength : 500MG
Approval Date : 2020-08-20
Application Number : 213504
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : Yes
TE Code :
Brand Name : URSO 250
Dosage Form : TABLET;ORAL
Dosage Strength : 250MG
Approval Date : 1997-12-10
Application Number : 20675
RX/OTC/DISCN : DISCN
RLD : Yes
TE Code :
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : Yes
TE Code :
Brand Name : URSO FORTE
Dosage Form : TABLET;ORAL
Dosage Strength : 500MG
Approval Date : 2004-07-21
Application Number : 20675
RX/OTC/DISCN : DISCN
RLD : Yes
TE Code :
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
RLD : No
TE Code :
Brand Name : URSODIOL
Dosage Form : CAPSULE;ORAL
Dosage Strength : 200MG
Approval Date : 2020-05-08
Application Number : 205789
RX/OTC/DISCN : RX
RLD : No
TE Code :
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
RLD : No
TE Code :
Brand Name : URSODIOL
Dosage Form : CAPSULE;ORAL
Dosage Strength : 400MG
Approval Date : 2020-05-08
Application Number : 205789
RX/OTC/DISCN : RX
RLD : No
TE Code :
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AB
Brand Name : URSODIOL
Dosage Form : CAPSULE;ORAL
Dosage Strength : 300MG
Approval Date : 2020-02-12
Application Number : 213200
RX/OTC/DISCN : RX
RLD : No
TE Code : AB

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code :
Brand Name : ACTIGALL
Dosage Form : CAPSULE;ORAL
Dosage Strength : 150MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Approval Date : 1987-12-31
Application Number : 19594
RX/OTC/DISCN : DISCN
RLD : No
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : Yes
TE Code : AB
Brand Name : ACTIGALL
Dosage Form : CAPSULE;ORAL
Dosage Strength : 300MG
Approval Date : 1987-12-31
Application Number : 19594
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AB

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Dosage Form : Suspension
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Dosage Form : Cream / Lotion / Ointment
Grade : Topical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Dosage Form : Tablet, Orodispersible Tablet
Grade : Oral
Category : Chewable & Orodispersible Aids, Co-Processed Excipients, Direct Compression, Fillers, Diluents & Binders, Taste Masking
Application : Chewable & Orodispersible Aids, Co-Processed Excipients, Direct Compression, Fillers, Diluents & Binders, Taste Masking
Excipient Details : Compressol® SM, co-processed polyol, is a DC excipient of mannitol & sorbitol with superior compactibility, low disintegration time & hygroscopicity.
Dosage Form : Capsule, Granule / Pellet, Tablet, Injectable / Parenteral
Grade : Parenteral, Oral
Category : Fillers, Diluents & Binders, Thickeners and Stabilizers
Application : Fillers, Diluents & Binders
Excipient Details : KoVidone® K25 is used as a low viscosity wet binder in solid dosage forms such as capsules and tablets.
Dosage Form : Cream / Lotion / Ointment, Gel, Injectable / Parenteral, Softgel Capsule, Softgels
Grade : Parenteral, Topical, Oral
Category : Fillers, Diluents & Binders, Film Formers & Plasticizers, Parenteral, Surfactant & Foaming Agents, Thickeners and Stabilizers, Topical
Brand Name : Polyethylene Glycol 400
Application : Fillers, Diluents & Binders, Film Formers & Plasticizers, Parenteral, Surfactant & Foaming Agents, Thickeners and Stabilizers, Topical
Excipient Details : PEG 400 is used as a suspending agent, stabilizer, plasticizer and filler in OSDs, liquids & semi-solids and as a solvent for parenteral formulations.
Dosage Form : Tablet
Grade : Oral (Pharma Grade)
Category : Direct Compression, Fillers, Diluents & Binders, Film Formers & Plasticizers
Application : Direct Compression, Fillers, Diluents & Binders, Film Formers & Plasticizers
Excipient Details : KoVidone® VA64 is used as a binder in tablets, direct compression binder, matrix formers in amorphous solid dispersions, and film-forming polymer.
Pharmacopoeia Ref : USP/NF, EP, JP, KP, IP, BP
Technical Specs : NA
Ingredient(s) : Polyvinylpyrrolidone/Vinyl Acetate Copolymer
Dosage Form : Capsule, Granule / Pellet, Tablet, Injectable / Parenteral
Grade : Parenteral, Oral
Category : Fillers, Diluents & Binders, Thickeners and Stabilizers
Grade : Oral
Category : Co-Processed Excipients, Fillers, Diluents & Binders
Application : Co-Processed Excipients, Fillers, Diluents & Binders
Excipient Details : ProBlend (SMCC) is a co-processed excipient consists of microcrystalline cellulose & colloidal silicon dioxide, used as a diluent & binder in OSDs.
Pharmacopoeia Ref : USP-NF, DMF, EXCiPAT, KOSHER, ...
Technical Specs : NA
Ingredient(s) : Microcrystalline Cellulose Excipients
Dosage Form : Tablet
Grade : Oral (Pharma Grade)
Category : Direct Compression, Fillers, Diluents & Binders, Film Formers & Plasticizers
Brand Name : KoVidone® Ultra VA64
Application : Direct Compression, Fillers, Diluents & Binders, Film Formers & Plasticizers
Excipient Details : KoVidone® Ultra VA64 is used as a tablet binder, direct compression binder, matrix former in amorphous solid dispersions, and film-forming polymer.
Pharmacopoeia Ref : USP/NF, EP, JP, KP, IP, BP
Technical Specs : NA
Ingredient(s) : Polyvinylpyrrolidone/Vinyl Acetate Copolymer
Brand Name : Lactose Monohydrate
Application : Parenteral
Excipient Details : Lactose monohydrate is used as a diluent in inhalation and lyophilized preparations.
Dosage Form : Cream / Lotion / Ointment, Suspension
Grade : Topical
Category : API Stability Enhancers, Thickeners and Stabilizers
Dosage Form : Cream / Lotion / Ointment, Capsule, Gel, Tablet
Grade : Oral, Topical
Category : API Stability Enhancers, Thickeners and Stabilizers
Application : API Stability Enhancers, Thickeners and Stabilizers
Excipient Details : Adsorbent, Moisture Protection, Stabilization of API
Pharmacopoeia Ref : USP-NF, JP, EP
Technical Specs : Also Available as FUJISIL-F
Ingredient(s) : Silicon Dioxide
Grade : Not Available
Category : API Stability Enhancers, Coating Systems & Additives, Controlled & Modified Release, Direct Compression, Granulation, Rheology Modifiers, Vegetarian Capsules
Application : API Stability Enhancers, Coating Systems & Additives, Controlled & Modified Release, Direct Compression, Granulation, Rheology Modifiers, Vegetarian Capsules
Excipient Details : Controlled Release, Direct Compression,Wet Granulation,Tablet Coating, Liquid Solutions and Suspensions
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Hydroxypropyl Methyl Cellulose
Dosage Form : Suspension, Tablet
Grade : Not Available
Category : Controlled & Modified Release, Rheology Modifiers, Thickeners and Stabilizers
Dosage Form : Capsule
Grade : Oral and Inhalation
Category : API Stability Enhancers, Vegetarian Capsules
Application : API Stability Enhancers, Vegetarian Capsules
Pharmacopoeia Ref : Certified Vegan, Non-GMO, Vege...
Technical Specs : "Water content – less than 9%, can be customized; Size # 00el -...
Ingredient(s) : Hydroxypropyl Methyl Cellulose
Dosage Form : Capsule
Grade : Oral
Category : API Stability Enhancers, Taste Masking, Vegetarian Capsules
Application : API Stability Enhancers, Taste Masking, Vegetarian Capsules
Pharmacopoeia Ref : Certified Vegan, Non-GMO, Vege...
Technical Specs : Size # 0-1
Ingredient(s) : Hydroxypropyl Methyl Cellulose
Global Sales Information
Dosage Form :
Dosage Strength : 20 Cps 150 Mg
Price Per Pack (Euro) : 6.63
Published in :
Country : Italy
RX/OTC/DISCN : Class C

Dosage Form :
Dosage Strength : 40 Cpr 50 Mg
Price Per Pack (Euro) : 7.9
Published in :
Country : Italy
RX/OTC/DISCN : Class C

Dosage Form : Capsule, hard
Dosage Strength : 250 mg
Price Per Pack (Euro) : 43.659
Published in :
Country : Norway
RX/OTC/DISCN :

Dosage Form : Capsule, hard
Dosage Strength : 250 mg
Price Per Pack (Euro) : 43.659
Published in :
Country : Norway
RX/OTC/DISCN :

Dosage Form : Capsule, hard
Dosage Strength : 500 mg
Price Per Pack (Euro) : 75.581
Published in :
Country : Norway
RX/OTC/DISCN :

Dosage Form : CAPSULE;ORAL
Dosage Strength : 300MG
Price Per Pack :
Published in :
Country : USA
RX/OTC/DISCN : RX

Dosage Form : CAPSULE;ORAL
Dosage Strength : 150MG **Federal Register determination tha...
Price Per Pack :
Published in :
Country : USA
RX/OTC/DISCN : DISCN

Dr. Falk Pharma GmbH
Dosage Form : Antic-calc Tablet, Film Coated
Dosage Strength : 500 mg
Price Per Pack (Euro) : 40.161
Published in :
Country : Norway
RX/OTC/DISCN :

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Dr. Falk Pharma GmbH
Dosage Form : Antic-calc Tablet, Film Coated
Dosage Strength : 500 mg
Price Per Pack (Euro) : 75.581
Published in :
Country : Norway
RX/OTC/DISCN :

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Dr. Falk Pharma GmbH
Dosage Form : Capsule, hard
Dosage Strength : 250 mg
Price Per Pack (Euro) : 43.659
Published in :
Country : Norway
RX/OTC/DISCN :

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ursodiol (Ursodeoxycholic acid)
Main Therapeutic Indication : Others
Currency : USD
2014 Revenue in Millions : -15%
2013 Revenue in Millions :
Growth (%) :

Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2017 Revenue in Millions : 52
2016 Revenue in Millions : 60
Growth (%) : -14

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
83
PharmaCompass offers a list of Ursodeoxycholic Acid API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Ursodeoxycholic Acid manufacturer or Ursodeoxycholic Acid supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ursodeoxycholic Acid manufacturer or Ursodeoxycholic Acid supplier.
PharmaCompass also assists you with knowing the Ursodeoxycholic Acid API Price utilized in the formulation of products. Ursodeoxycholic Acid API Price is not always fixed or binding as the Ursodeoxycholic Acid Price is obtained through a variety of data sources. The Ursodeoxycholic Acid Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Antigall manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Antigall, including repackagers and relabelers. The FDA regulates Antigall manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Antigall API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Antigall manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Antigall supplier is an individual or a company that provides Antigall active pharmaceutical ingredient (API) or Antigall finished formulations upon request. The Antigall suppliers may include Antigall API manufacturers, exporters, distributors and traders.
click here to find a list of Antigall suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Antigall DMF (Drug Master File) is a document detailing the whole manufacturing process of Antigall active pharmaceutical ingredient (API) in detail. Different forms of Antigall DMFs exist exist since differing nations have different regulations, such as Antigall USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Antigall DMF submitted to regulatory agencies in the US is known as a USDMF. Antigall USDMF includes data on Antigall's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Antigall USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Antigall suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Antigall Drug Master File in Japan (Antigall JDMF) empowers Antigall API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Antigall JDMF during the approval evaluation for pharmaceutical products. At the time of Antigall JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Antigall suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Antigall Drug Master File in Korea (Antigall KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Antigall. The MFDS reviews the Antigall KDMF as part of the drug registration process and uses the information provided in the Antigall KDMF to evaluate the safety and efficacy of the drug.
After submitting a Antigall KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Antigall API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Antigall suppliers with KDMF on PharmaCompass.
A Antigall CEP of the European Pharmacopoeia monograph is often referred to as a Antigall Certificate of Suitability (COS). The purpose of a Antigall CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Antigall EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Antigall to their clients by showing that a Antigall CEP has been issued for it. The manufacturer submits a Antigall CEP (COS) as part of the market authorization procedure, and it takes on the role of a Antigall CEP holder for the record. Additionally, the data presented in the Antigall CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Antigall DMF.
A Antigall CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Antigall CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Antigall suppliers with CEP (COS) on PharmaCompass.
A Antigall written confirmation (Antigall WC) is an official document issued by a regulatory agency to a Antigall manufacturer, verifying that the manufacturing facility of a Antigall active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Antigall APIs or Antigall finished pharmaceutical products to another nation, regulatory agencies frequently require a Antigall WC (written confirmation) as part of the regulatory process.
click here to find a list of Antigall suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Antigall as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Antigall API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Antigall as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Antigall and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Antigall NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Antigall suppliers with NDC on PharmaCompass.
Antigall Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Antigall GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Antigall GMP manufacturer or Antigall GMP API supplier for your needs.
A Antigall CoA (Certificate of Analysis) is a formal document that attests to Antigall's compliance with Antigall specifications and serves as a tool for batch-level quality control.
Antigall CoA mostly includes findings from lab analyses of a specific batch. For each Antigall CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Antigall may be tested according to a variety of international standards, such as European Pharmacopoeia (Antigall EP), Antigall JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Antigall USP).